GlaxoSmithKline Pays $3 billion to Settle Unfair Practices regarding the Sale of Avandia

GlaxoSmithKline, one of the world’s largest drug manufacturers, settled a number of claims resulting from government investigations including one tied to the sale of diabetes drug, Avandia, which has been associated with increased heart risks, and one related to off-label marketing of other drug products. GlaxoSmithKline contends that as a result of claims such as these, it has revamped its compliance and marketing practices to avoid risks of illegal and improper marketing.

For more information see: http://www.foxbusiness.com/markets/2011/11/03/glaxosmithkline-settles-us-drug-rows-for-3-billion/#ixzz1ceogx5jt